Actos' Bladder Cancer Signal May Hinge On Dose, Duration Of Use
This article was originally published in The Pink Sheet Daily
Executive Summary
A five-year interim analysis of a 10-year epidemiological study showed no significant overall increased risk between exposure to Takeda's pioglitazone and bladder cancer, although an increased risk was seen among patients with the highest cumulative dose and the longest duration of exposure.
You may also be interested in...
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
In an age of diabetes drug safety scares, will patients turn off of the thiazolidinedeione class altogether, or will the warning go unnoticed?
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
In an age of diabetes drug safety scares, will patients turn off of the thiazolidinedeione class altogether, or will the warning go unnoticed?
First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
TOKYO - Takeda Pharmaceutical Co. bestseller Actos has been withdrawn for new patients in France and Germany due to a long-suspected bladder cancer risk. Besides shrinking some of the excitement around the European boost Takeda received with its acquisition of Nycomed AS, the withdrawals also call into question the remaining revenue Actos can generate before its main patents expire